| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
10.91(B) |
| Last
Volume: |
1,933,966 |
Avg
Vol: |
1,913,064 |
| 52
Week Range: |
$56.27 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
103,519 |
108,398 |
180,881 |
290,334 |
| Total Sell Value |
$6,219,303 |
$6,570,910 |
$12,429,896 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
49 |
52 |
65 |
100 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Condella Sarah |
EVP, Human Resources |
• – – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,311 |
91,616 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,137 |
33,474 |
|
- |
|
| Coward D Scott |
Director |
– • – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,194 |
36,928 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,492 |
1,217,722 |
|
- |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,677 |
26,331 |
|
- |
|
| Herriott James |
General Counsel |
• – – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,887 |
11,449 |
|
- |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,954 |
23,255 |
|
- |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2023-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,954 |
9,441 |
|
- |
|
| Coward D Scott |
Director |
– • – |
2023-02-22 |
4 |
AS |
$62.72 |
$63,159 |
D/D |
(1,007) |
27,734 |
|
44% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-02-22 |
4 |
AS |
$62.72 |
$89,690 |
D/D |
(1,430) |
24,337 |
|
44% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-02-22 |
4 |
AS |
$62.72 |
$298,798 |
D/D |
(4,764) |
1,195,230 |
|
44% |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2023-02-22 |
4 |
AS |
$62.72 |
$52,559 |
D/D |
(838) |
5,487 |
|
44% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-02-22 |
4 |
AS |
$62.72 |
$64,790 |
D/D |
(1,033) |
85,305 |
|
44% |
|
| Herriott James |
General Counsel |
• – – |
2023-02-22 |
4 |
AS |
$62.72 |
$24,963 |
D/D |
(398) |
9,562 |
|
44% |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2023-02-22 |
4 |
AS |
$62.72 |
$169,971 |
D/D |
(2,710) |
19,301 |
|
44% |
|
| Coward D Scott |
Director |
– • – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
28,741 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,112 |
25,767 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,374 |
1,199,994 |
|
- |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,729 |
6,325 |
|
- |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
86,338 |
|
- |
|
| Herriott James |
General Counsel |
• – – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
865 |
9,960 |
|
- |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,897 |
22,011 |
|
- |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-02-16 |
4 |
AS |
$63.91 |
$68,767 |
D/D |
(1,076) |
84,090 |
|
48% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2023-02-15 |
4 |
AS |
$65.59 |
$122,391 |
D/D |
(1,866) |
22,655 |
|
43% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2023-02-15 |
4 |
AS |
$65.59 |
$958,729 |
D/D |
(14,617) |
1,189,620 |
|
43% |
|
777 Records found
|
|
Page 6 of 32 |
|
|
1.94 (3.06%) 
